September 2012

Founded in 1913 as a tuberculosis sanatorium, City of Hope today enjoys a reputation as a leading research, treatment, and education center for those with cancer, diabetes, and other life-threatening diseases.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Patients 75 years of age or older with stage III colon cancer may expect a survival benefit from adjuvant chemotherapy that rivals that previously reported in younger patients.

Integrative model unites physicians, hospitals, and payers to deliver evidence-based care and control cancer costs.

The addition of aprepitant to standard antiemetic prophylaxis significantly improved the complete response rate in patients with germ cell tumors undergoing 5-day cisplatin combination chemotherapy regimens.

Nearly 2 years after a landmark study supported CT for people at high risk of developing lung cancer, questions persist about the complexities of implementing an early detection program.

The addition of sorafenib to first-line gemcitabine/cisplatin does not appear to lengthen survival in patients with advanced, nonsquamous, non–small cell lung cancer.

Driven by changes in reimbursement and standards of care, independent community oncology practices continue to dwindle.

Dose-dense induction with high-dose chemotherapy/autologous stem-cell transplantation is reasonable for use as first-line treatment of transplantation-eligible patients with systemic peripheral T-cell lymphomas.

An interview with Giorgio V. Scagliotti, MD, who has played a prominent role in researching and developing therapies to attack molecular targets.

During the 11th International Congress on The Future of Breast Cancer, Hope Rugo, MD, offered a snapshot of the research community's progress in the study and treatment of the disease.

Decitabine produced a higher response rate than standard therapies in older patients with newly diagnosed acute myeloid leukemia without major differences in safety.

A new formulation of trastuzumab that is administered subcutaneously appears to be as effective as the approved bodyweight-based intravenous regimen in women with HER2-positive breast cancer.

Pretreatment serum lactate dehydrogenase is a prognostic factor in poor-risk patients with renal cell carcinoma and also a predictive factor for a survival benefit from treatment with temsirolimus.

A consortium of over 442 global investigators at 32 institutions recently reported results in over 30 publications of a decade of work from the Encyclopedia of DNA Elements project.